{"url_path":"/sec/ardt/8-k/2026-06-30/item-5-02","section_key":"item-5-02","section_title":"Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-30","source_url":"https://www.sec.gov/Archives/edgar/data/1756655/0001628280-26-046247-index.html","accession_number":"0001628280-26-046247","cik":"0001756655","ticker":"ARDT","issuer_name":"Ardent Health, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1756655/0001628280-26-046247-index.html","primary_entity_key":"0001756655","primary_entity_name":"Ardent Health, Inc."},"word_count":298,"has_tables":true,"body_markdown":"Item 5.02.     Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.\n\nAs previously disclosed, on June 2, 2026 (the “Effective Date”), Ardent Health, Inc. (the “Company”) announced that Martin J. Bonick had departed from his role as President and Chief Executive Officer of the Company and had stepped down from the Company’s Board of Directors (the “Board”), effective as of the Effective Date.\n\nIn connection with Mr. Bonick’s departure from his role as President and Chief Executive Officer of the Company, on June 26, 2026, Mr. Bonick and an affiliate of the Company entered into a separation agreement and general release, effective as of the Effective Date (the “Separation Agreement”).\n\nPursuant to the Separation Agreement, Mr. Bonick will receive certain severance benefits that are consistent with a termination of employment by the Company without “Cause” (as defined in Mr. Bonick’s employment agreement with the Company), as described in the Company’s Definitive Proxy Statement filed with the U.S. Securities and Exchange Commission on April 8, 2026, subject to his non-revocation of the Separation Agreement and the release of claims contained in the Separation Agreement. The Separation Agreement also provides that the vesting and/or forfeiture of Mr. Bonick’s time-based restricted stock units, performance-based restricted stock units and shares of restricted stock will be governed by the terms of the Company’s incentive award plan and Mr. Bonick’s award agreements granted thereunder. Under the Separation Agreement, Mr. Bonick is subject to non-competition and non-solicitation covenants for twelve months following the Effective Date.\n\nThe foregoing description of the Separation Agreement is qualified in its entirety by reference to the full text of the Separation Agreement, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference."}